Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | +2.60% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.15 | N/A | +2.60% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management remains focused on advancing their pipeline. They emphasized the significance of future developments for the company.
Management expressed optimism about ongoing clinical trials.
They highlighted the importance of upcoming data releases in the near future.
Viking Therapeutics reported a loss per share of $0.15, which was slightly better than expected. However, the lack of revenue data and no guidance led to a 2.36% decline in stock price. Investors may be cautious as they await more information on clinical trials and future data releases.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Medpace Holdings, Inc.